Deprecated: Creation of dynamic property cls_session::$session_data_table is deprecated in /www/sites/www.188bio.com/index/systems/cls_session.php on line 49
MedKoo Biosciences/MGCD-265-analog/201841/500mg188bio精品生物—专注于实验室精品爆款的电商平台 - 蚂蚁淘旗下精选188款生物医学科研用品
您好,欢迎您进入188进口试剂采购网网站! 服务热线:4000-520-616
蚂蚁淘商城 | 现货促销 | 科研狗 | 生物在线
产品资料

MedKoo Biosciences/MGCD-265-analog/201841/500mg

MGCD265-analog,CAS#875337-44-3,isstructurallyrelatedtoMGCD-265(Glesatinib).MGCD-265-analogisanorallybioavailablemultitargetedtyrosinekinaseinhibitorwithpotentialantineoplasticactivity.MGCD-265-analogwasintroducedtotheresearchcommunityduetothewrongstructurepublishedinsomedatabaseandpublications.MGCD-265-analoghasbeensoldasMGCD-265bymanyreagentvendorssince2012.Asof4/28/2016,manydrug-relateddatabaseandsuppliersstilllistedawrongstructureforMGCD-265.MGCD-265(Glesatinib)hasCAS#936694-12-1.

MedKooCat#:201841
Name:MGCD-265-analog
CAS#:875337-44-3
ChemicalFormula:C26H20FN5O2S2
ExactMass:517.10424
MolecularWeight:517.6
ElementalAnalysis:C,60.33;H,3.89;F,3.67;N,13.53;O,6.18;S,12.39


Synonym:MGCD-265-analog;MGCD265-analog;MGCD265-analog.Glesatinib-analog.

IUPAC/ChemicalName:N-((3-fluoro-4-((2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yl)oxy)phenyl)carbamothioyl)-2-phenylacetamide

InChiKey:UFICVEHDQUKCEA-UHFFFAOYSA-N

InChiCode:InChI=1S/C26H20FN5O2S2/c1-32-14-20(29-15-32)23-13-19-25(36-23)22(9-10-28-19)34-21-8-7-17(12-18(21)27)30-26(35)31-24(33)11-16-5-3-2-4-6-16/h2-10,12-15H,11H2,1H3,(H2,30,31,33,35)

SMILESCode:O=C(NC(NC1=CC=C(OC2=C3C(C=C(C4=CN(C)C=N4)S3)=NC=C2)C(F)=C1)=S)CC5=CC=CC=C5


TechnicalData

Appearance:
Solidpowder

Purity:
>98%

ShippingCondition:
Shippedunderambienttemperatureasnon-hazardouschemical.ThisproductisstableenoughforafewweeksduringordinaryshippingandtimesentinCustoms.

StorageCondition:
Dry,darkandat0-4Cforshortterm(daystoweeks)or-20Cforlongterm(monthstoyears).

Solubility:
SolubleinDMSO,notinwater

ShelfLife:
>5yearsifstoredproperly

DrugFormulation:
ThisdrugmaybeformulatedinDMSO

StockSolutionStorage:
0-4Cforshortterm(daystoweeks),or-20Cforlongterm(months).

HarmonizedSystemCode:
293490


AdditionalInformation

MGCD265isanoveltargetedcancertherapeuticdiscoveredbyMethylGenethatinhibitstheMetandVEGFreceptortyrosinekinases.TheabnormalactivationofMetisinvolvedintumordevelopment,metastasisandsurvivalandtheVEGFkinaseisresponsIBLefortheinappropriateformationofbloodvessels(angiogenesis)thatnourishthetumor.Inpreclinicalstudies,MGCD265demonstratednanomolarpotencyinenzymeandcellularassaysandupto100%oftumorgrowthinhibitioninabroadrangeofxenograftmodels.
 
DevelopmentStatusofMGCD265:IntheongoingPhase1program,MGCD265isbeingadmiNISTeredorallyinpatientswithadvancedcancers.Thecompoundhasdemonstratedafavorablesafetyprofileandcanbecombinedsafelywithothercancertherapeuticssuchasdocetaxel(Taxotere®)anderlotinib(Tarceva®).ThesetherapeuticswereselectedforcombinationstudiesbasedonpreclinicaldatathatdemonstratedthecombinationofMGCD265anderlotinibandofMGCD265anddocetaxelshowedgreateranti-tumoractivitycomparedtoeachdrugadministeredalone.Todate,theCompanyhasinitiatedthreeclinicalstudies.(source:http://methylgene.com,accesseddate:2/1/2012)
  
 


References

J.M.Besterman,M.Fournel,I.Dupont,C.Bonfils,M.Dubay,H.Ste-Croix,C.R.Maroun;MethylGene,Inc.,Montreal,QC,Canada,PotentpreclinicalantitumoractivityofMGCD265,anoralMet/VEGFRkinaseinhibitorinphaseIIclinicaldevelopment,incombinationwithtaxanesorerlotinib,JClinOncol28,2010(suppl;abstre13595).

新闻动态
行业前沿
技术文章
最新产品